NICE

News

NICE reverses stance on Merck's Bavencio for bladder cancer

Last year, NICE said that Merck KGaA/Pfizer's Bavencio was too expensive for routine in NHS use as a first-line maintenance treatment for bladder cancer, even though the drug is the only ca

News

NICE expands access to real-time glucose monitoring for diab...

More than 250,000 people living with type 1 diabetes in the UK will be offered real-time continuous glucose monitoring (CGM) technology, reducing their reliance on fingerprick testing, acco

News

NICE firms up NHS use of Vimizim for Morquio A syndrome

In 2015, NICE said that BioMarin's Vimizim could be used to treat patients with the ultra-rare disease Morquio A syndrome, while real-world data was collected on its efficacy.

Market Access

Time to ask companies why they don’t submit to NICE?

Companies can choose whether or not to submit to NICE to have their products appraised.

News

NICE says no to Keytruda in triple-negative breast cancer

There isn't enough evidence to support the use of Merck & Co/MSD's Keytruda in combination with chemotherapy as a first-line treatment for advanced triple negative breast cancer, accord

News

GSK’s ZEJULA gets green light for NHS use

The UK’s National Institute for Health and Care Excellence (NICE) has recommended GlaxoSmithKline’s (GSK) ZEJULA (niraparib) for some forms of ovarian, fallopian tube, and peritoneal cancer

NICE reverses stance on Merck's Bavencio for bladder cancer

NICE expands access to real-time glucose monitoring for diab...

NICE firms up NHS use of Vimizim for Morquio A syndrome

Time to ask companies why they don’t submit to NICE?

NICE says no to Keytruda in triple-negative breast cancer

GSK’s ZEJULA gets green light for NHS use

AI giant Anthropic buys Coefficient Bio for $400m

Using AI-driven synthetic personas to take your insights fur...

NICE

Editor's Picks